RecruitingNot ApplicableNCT03203239

Red Light Treatment in Peripheral Artery Disease

Vasodilatory Effects of Light on Peripheral Artery Disease


Sponsor

University of Alabama at Birmingham

Enrollment

40 participants

Start Date

Jan 17, 2018

Study Type

INTERVENTIONAL

Conditions

Summary

Subjects with a known diagnosis of peripheral artery disease as measured by an abnormal ankle brachial index (\<.9 or \>1.1) will undergo a single 5 min exposure of 670 nm light, 1 cm above the gastrocnemius muscle. Blood flow will be measured by infusion of ultrasound contrast and subsequent acquisition of ultrasound images. 2 blood samples will be collected for measurement of nitric oxide metabolites.


Eligibility

Min Age: 18 YearsMax Age: 85 Years

Inclusion Criteria2

  • Participants will be subjects between the ages of 18 and 85 who have been diagnosed with peripheral artery disease. Men and women will be recruited for participation. All ethnicities will be included in this study.
  • Diagnosis of peripheral artery disease is defined as an Ankle Brachial index of \<0.9 or greater than 1.1 either at rest or during treadmill exercise.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DEVICERed Light (670 nm energy)

Light Emitting Diode light source (670 nm wavelength with output up to 75mW/cm2) will be placed over the gastrocnemius muscle. The light will be on for 5 minutes.

DRUGOctafluoropropane

All subjects will undergo infusion of octafluoropropane to measure peripheral blood flow.


Locations(1)

Medical College of Wisconsin

Milwaukee, Wisconsin, United States

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT03203239


Related Trials